Schrödinger (NASDAQ:SDGR) Shares Down 5.4% – Should You Sell?

Schrödinger, Inc. (NASDAQ:SDGR)’s share price fell 5.4% on Tuesday . The company traded as low as $22.14 and last traded at $22.44. 224,873 shares were traded during trading, a decline of 70% from the average session volume of 744,017 shares. The stock had previously closed at $23.73.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on SDGR shares. Piper Sandler cut their target price on shares of Schrödinger from $50.00 to $45.00 and set an “overweight” rating for the company in a research report on Thursday, February 27th. KeyCorp lifted their price objective on Schrödinger from $25.00 to $27.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $32.29.

Schrödinger Price Performance

The stock’s 50-day simple moving average is $22.75 and its two-hundred day simple moving average is $20.72. The firm has a market capitalization of $1.62 billion, a P/E ratio of -9.42 and a beta of 1.62.

Schrödinger (NASDAQ:SDGR) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.20). The business had revenue of $88.32 million during the quarter, compared to analysts’ expectations of $83.20 million. Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. On average, analysts forecast that Schrödinger, Inc. will post -2.37 earnings per share for the current fiscal year.

Insider Transactions at Schrödinger

In other Schrödinger news, CFO Geoffrey Craig Porges sold 5,491 shares of Schrödinger stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $21.76, for a total value of $119,484.16. Following the sale, the chief financial officer now directly owns 27,544 shares in the company, valued at approximately $599,357.44. The trade was a 16.62 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 8.60% of the company’s stock.

Institutional Investors Weigh In On Schrödinger

Large investors have recently made changes to their positions in the company. Avanza Fonder AB bought a new position in Schrödinger during the fourth quarter valued at approximately $577,000. Barclays PLC raised its holdings in shares of Schrödinger by 421.6% during the 3rd quarter. Barclays PLC now owns 107,554 shares of the company’s stock worth $1,995,000 after acquiring an additional 86,933 shares in the last quarter. State Street Corp boosted its position in shares of Schrödinger by 1.8% during the 3rd quarter. State Street Corp now owns 2,155,620 shares of the company’s stock valued at $39,987,000 after acquiring an additional 38,972 shares during the last quarter. Quest Partners LLC boosted its position in shares of Schrödinger by 861.0% during the 3rd quarter. Quest Partners LLC now owns 43,773 shares of the company’s stock valued at $812,000 after acquiring an additional 39,218 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its stake in Schrödinger by 60.2% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,510,518 shares of the company’s stock worth $67,718,000 after acquiring an additional 1,319,464 shares during the last quarter. 79.05% of the stock is owned by institutional investors.

Schrödinger Company Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.